Clevudine: A promising therapy for the treatment of chronic hepatitis B

Expert Opinion on Investigational Drugs

Volumn 17, Issue 12, 2008, Pages 1963-1974

  Asselah, Tarik ^a   Lada, Olivier ^a   Moucari, Rami ^a   Marcellin, Patrick ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chronic hepatitis B; Clevudine; HBsAg

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; PRADEFOVIR; TELBIVUDINE; TENOFOVIR DISOPROXIL; VALTORCITABINE; VIRUS DNA; 2'-FLUORO-5-METHYLARABINOSYLURACIL; ANTIVIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B VACCINE; NUCLEOSIDE; UNCLASSIFIED DRUG; URACIL ARABINOSIDE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DNA VIRUS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECONOMIC ASPECT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; LONG TERM CARE; MONOTHERAPY; MORTALITY; NONHUMAN; PATIENT SELECTION; REVIEW; SCREENING TEST; SEROCONVERSION; SEROPREVALENCE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; ANIMAL; DRUG SCREENING; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DRUG EVALUATION, PRECLINICAL; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES;

EID: 58149375894     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802535760     Document Type: Review

References (79)

1. World Health Organization: Hepatitis Fact Sheet. WHO/204; Revised October 2000. Available from: http://www.who.int/inf-fs/fact204.html Accessed September 23, 2005
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infec Dis 2005;5:558-567 (Pubitemid 41196755)
3. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-1129 (Pubitemid 38298992)
4. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-1683
5. Fattovich G. Natural history of hepatitis B. J Hepatol 2003;39 (suppl 1):S50-8 (Pubitemid 37222647)
6. Brown RE, De Cock E, Colin X, et al. Hepatitis B management cost in France, Italy, Spain and the United Kingdom. J Clin Gastroenterol 2004;38:S169-74
7. Yuen MF, Lai CL. Treatment for hepatitis B: a public health perspective. J Clin Gastroenterol 2004;38(suppl 10): S134-5
8. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38:S158-68
9. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-101 (Pubitemid 38365759)
10. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61 (Pubitemid 36002487)
11. Zarski JP, Marcellin P, Leroy V, et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol 2006;45(3):355-360 (Pubitemid 44160628)
12. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterol 2004;127(Suppl 1):S35-50
13. Bruix J, Sherman M, Llovet JM, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430
14. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-1859
15. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529-538 (Pubitemid 44307383)
16. Marcellin P, Pequignot F, Delarocque, et al. Mortality related to chronic Hepatitis B and chronic Hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008;48(2):183-184
17. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45(3):579-587
18. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45(4):1056-1075 • Excellent Summary of Management of Hepatitis B.
19. Craxi A, Yurdaydin C. From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference. J Hepatol 2006;44(6):1186-1195
20. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterol 2004;126(4):1005-1014
21. Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. J Hepatol 2007;47(4):608-617 (Pubitemid 47331764)
22. De Jongh FE, Janssen HL, De Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterol 1992;103:1630-1635
23. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-298
24. Brunetto MR, Oliveri F, Coco B, et al. The outcome of chronic anti HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-270 (Pubitemid 34146434)
25. Iloeje UH, Yang HI, Su J Jen, et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterol 2006
26. Yang HI, Lu SN, Liaw YF, et al. for the Taiwan Community-Based Cancer Screening Project Group. Hepatitis B antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174
27. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
28. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507-539 • Recommendations of Management of Hepatitis B. (Pubitemid 46374607)
29. Marcellin P, Asselah T, Boyer. Treatment of chronic hepatitis B. J Viral Hepat 2005;12(4):333-345
30. EASL International Consensus Conference on Hepatitis B. Consensus Statement (long version). J Hepatol 2003;39(Suppl 1):S3-25
31. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5(8):890-897 • Rapport of a Workshop on Management of Hepatitis B.
32. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993;119:312-323
33. Cooksley G, Piratvisuth T, Lee SD, et al. Peginterferon alpha 2a (40KDa) : an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305 (Pubitemid 36801917)
34. Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365(9454):123-129
35. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682-2695 • Clinical Trial, approval for Peginterferon Alfa-2a. (Pubitemid 40861907)
36. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206-1217 • OO Clinical Trial, approval for Peginterferon Alfa-2a. (Pubitemid 39296307)
37. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142(4):240-250
38. Marcellin P, Bonino F, Lau GK, et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with Peginterferon alpha 2a ± lamivudine: 3 years follow-up results [abstract 53]. J Hepatol 2007;46(Suppl 1)
39. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44(3):675-684
40. Lai CL, Chien RW, Leung NWY, et al. Lamivudine Study Group. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68
41. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15):1521-1531 (Pubitemid 39315319)
42. Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-1703
43. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816 (Pubitemid 36245757)
44. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen negative hepatitis B. N Engl J Med 2003;348:800-807 • Clinical Trial, approval for Adefovir dipivoxil. (Pubitemid 36245756)
45. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352(26):2673-2681 (Pubitemid 41007822)
46. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterol 2006;131:1743-1751
47. Marcellin P, Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J Hepatol 2005;43:920-923 (Pubitemid 41627973)
48. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine resistant hepatitis B in pre and post liver transplantation patients. Hepatology 2003;38:1419-1427
49. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co infected with HIV 1 and lamivudine resistant hepatitis B virus: an open label pilot study. Lancet 2001;358:718-723
50. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(10):1011-20. Erratum in: N Engl J Med 2006;354(17):1863 • Clinical Trial, approval for Entecavir. (Pubitemid 43357805)
51. Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001-1010 • Clinical Trial, approval for Entecavir. (Pubitemid 43357804)
52. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48(1):99-108
53. Pierra C, Imbach JL, De Clerq E, et al. Synthesis and antiviral evaluation of some beta-L-'-3′dideoxy-5-chloropyrimidine nucleosides and pronucleotides. Antiviral Res 2000;45:169-183
54. Lim SG, Ng TM, Kung N, et al. Emtricitabine FTCB-301 Study Group. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166(1):49-56
55. Lai CL, Leung N, Teo EK, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterol 2005;129(2):528-536
56. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357(25):2576-2588 • Clinical Trial, approval for Telbivudine. (Pubitemid 350294224)
57. Heathcote EJ, Gane E, Deman R, et al. A randomized, double-bind, comparison of Tenofovir (TDF) versus Adefovir Dipivoxil (ADV) for the treatment of HBe Ag-negative Chronic Hepatitis B (CHB): study GS-US-174-10103 Hepatology 2007;46:861A
58. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-bind, comparison of Tenofovir (TDF) versus Adefovir Dipivoxil (ADV) for the treatment of HBe Ag-negative Chronic Hepatitis B (CHB): study GS-US-174-10102 Hepatology 2007;46:290A
59. Chu CK, Ma T, Shanmuganathan K, Wang C, et al. Use of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995;39(4):979-981
60. Yao GQ, Liu SH, Chou E, et al. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil. Biochem Pharmacol 1996;51(7):941-947
61. Aguesse-Germon S, Liu H, Chevallier M, et al. Inhibitory effect of 2′fluoro-5-methyl-beta-L-arabinofuranosyl uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother 1998;42:369-376
62. Balakrishna PS, Liu SH, Zhu YL, et al. Inhibition of hepatitis B virus by a novel L-nucleoside, 2 -fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother 1996;40:380-386
63. Ma T, Pai SB, Zhu YL, Lin JS, et al. Structure - activity relationships of 1- (2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem 1996;39(14):2835-2843 (Pubitemid 26240351)
64. Seignères B, Pichoud C, Martin P, et al. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002;36(3):710-722
65. Chong Y, Chu CK. Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies. Bioorg Med Chem Lett 2002;12(23):3459-3462 (Pubitemid 35292469)
66. Korba BE, Cote PJ, Menne S, et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 2004;9(6):937-952
67. Tennant BC. Gerin JL. The woodchuck model of hepatitis B virus infection. In: Arias IM, Boyer J, Fausto N, (editors.), The liver: biology and pathology. 3rd edition. Raven Press, Ltd., New York, 1994. p. 1455-1466
68. Menne, Stephan, Roneker, et al. Immunization with Surface Antigen Vaccine Alone and after Treatment with 1-(2-Fluoro-5-Methyl-{beta}-L-Arabinofuranosyl)- Uracil (L-FMAU) Breaks Humoral and Cell-Mediated Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection. J Virol 2002;76:5305-5314 (Pubitemid 34517881)
69. Peek SF, Cote PJ, Jacob JR, et al. Antiviral activity of clevudine against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks. Hepatology 2001;33:254-266
70. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of Hepadnavirus Loss from the Liver during Inhibition of Viral DNA Synthesis. J Virol 2001;75:311-322
71. Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004;101(2):638-640 (Pubitemid 38084689)
72. Casey J, Cote PJ, Toshkov IA, et al. Clevudine Inhibits Hepatitis Delta Virus Viremia: a Pilot Study of Chronically Infected Woodchucks. Antimicrob Agents Chemother 2005;49:4396-4399
73. Yamamoto T, Litwin S, Zhou T, et al. Mutations of the Woodchuck Hepatitis Virus Polymerase Gene That Confer Resistance to Lamivudine and 2′-Fluoro-5-Methyl-{beta}-L-Arabinofuranosyluracil. J Virol 2002;76:1213-1223 (Pubitemid 34066425)
74. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10(5):625-633
75. Marcellin P, Mommeja-Marin H, Sacks SL, et al. A Phase II dose escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-148
76. Lim SG, Leung N, Hann HL, et al. Clinical trial: a Phase II, randomized study evaluating the safety, pharmacokinetics and antiviral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther 2008;27(12):1282-1292
77. Lee HS, Chung YH, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2006;43(5):982-988
78. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-1178
79. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-1048 • Clinical Trial for Clevudine